This article is more than 5 years old. Information may no longer be current.
Top 10 Stories of 2011
Click Here to Manage Email Alerts
At the end of each year, the Endocrine Today Editorial Board votes on the top 10 stories of the year — the stories considered having the most significant effect on the field of endocrinology. The votes have been tallied, and listed below are the choices for the top stories of 2011. As always, we welcome any reader comments about the list or about the effect that the topics covered in these stories will have on health care. Best wishes for a great 2012.
– Stacey L. Fisher, Managing Editor of Endocrine Today
Research field buzzing with interest about positive effects of metformin on cancer
As more data become available, excitement continues to build about the possible links between metformin and cancer. Two speakers discussed the future of this exciting field of research at the EASD 47th Annual Meeting.
Read more here
New figures highlight worsening diabetes epidemic
The number of people with diabetes in 2011 has reached 366 million, according to Diabetes Atlas figures recently released by the International Diabetes Federation.
Read more here
FDA approves combination sitagliptin, simvastatin
The FDA approved of a fixed-dose combination therapy containing sitagliptin and simvastatin for the treatment of adults with type 2 diabetes and high cholesterol.
Read more here
Diabetes–cancer link raises flags for endocrinologists
Accumulating data provide more evidence of the negative and positive relationships between diabetes therapies and cancer risk.
Read more here
Fenofibric acid may not lower risk for MI, stroke
The FDA announced that fenofibric acid may not lower myocardial infarction or stroke risk. The warning label of the drug has been amended accordingly.
Read more here
FDA panel advises against approval of dapagliflozin
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 that dapagliflozin, an investigational sodium-glucose co-transporter 2 inhibitor, should not be approved as an adjunct to diet and exercise for the management of type 2 diabetes.
Read more here
Investigational drugs may expand medical treatment of Cushing’s syndrome
Endocrinologists face many challenges when treating patients with Cushing’s syndrome. Diagnosis can be difficult because many of the disease’s characteristics, such as obesity, depression and hypertension, are also common in the general population.
Read more here
IOM report sets new dietary intake levels of calcium, vitamin D
Most adults need no more than 600 IU of vitamin D per day to maintain health, and those aged 71 years and older may need as much as 800 IU, according to a report from the Institute of Medicine.
Read more here
AACE releases new guidelines for diabetes management
Addressing prevention and treatment of diabetes has become a primary concern for endocrinologists. Consequently, the American Association of Clinical Endocrinologists issued new guidelines for developing a comprehensive care plan to manage diabetes.
Read more here
Osteoporosis management remains a challenge for endocrinologists
Despite new guidelines and updated tools, diagnosing and treating patients with osteoporosis remains a challenge, a speaker said at the American Association of Clinical Endocrinologists 20th Annual Meeting.
Read more here